Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk - A Digital Monograph

This digital monograph, featuring video snippets and key slides from the 2015 CMHC Annual meeting examines current lipid guidelines, the unmet need and residual risk of poorly controlled LDL-C, and exciting genetic insights that have expanded treatment targets. Experts discuss the latest information on novel LDL lowering therapies, including PCSK9 inhibitors. Clinical case examples are presented to provide tactics for treatment intensification and how best to integrate new therapies into management plans for high-risk patients.

LDL-C Focused Cardioprotection: What Do Recent Trials and Global Lipid Guidelines Tell Us?
Chairperson:
Christie M. Ballantyne, MD
Genetic and Mechanistic Insights into Novel Targets and Treatment Advances for LDL Lowering
Presenter:
Jay D. Horton, MD
Clinical Evidence for New Therapeutic Options: Focus on PCSK9 Inhibitors
Presenter:
Jennifer G. Robinson, MD, MPH
Special Considerations in Familial Hypercholesterolemia
Presenter:
Patrick M. Moriarty, MD
Panel Discussion: Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk
Moderator:
Christie M. Ballantyne, MD
Discussants:
Jay D. Horton, MDJennifer G. Robinson, MD, MPHPatrick M. Moriarty, MD